Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

10.0%

4 terminated out of 40 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed with results

Key Signals

5 with results67% success

Data Visualizations

Phase Distribution

40Total
Early P 1 (1)
P 1 (33)
P 2 (6)

Trial Status

Recruiting15
Completed8
Unknown6
Active Not Recruiting4
Terminated4
Not Yet Recruiting3

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (40)

Showing 20 of 20 trials
NCT06307795Phase 1RecruitingPrimary

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06545331Phase 1RecruitingPrimary

Study of XB010 in Subjects With Solid Tumors

NCT05581004Phase 1RecruitingPrimary

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06328439Phase 1Active Not RecruitingPrimary

A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT07469774Phase 1Not Yet RecruitingPrimary

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT07461181Phase 1Active Not RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT07202364Phase 2Recruiting

A Study of YL202 in Patients With Advanced Solid Tumors

NCT07446049Phase 2Not Yet RecruitingPrimary

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

NCT07066657Phase 1RecruitingPrimary

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT07318649Phase 2Not Yet RecruitingPrimary

Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation

NCT05012618Phase 1TerminatedPrimary

A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

NCT06107686Phase 2Recruiting

A Study of YL202 in Selected Patients With Advanced Solid Tumors

NCT04511845Phase 1Active Not RecruitingPrimary

A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

NCT06349811Phase 1RecruitingPrimary

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05205109Phase 1RecruitingPrimary

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

NCT05830539Phase 1CompletedPrimary

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

NCT05473156Phase 1RecruitingPrimary

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

NCT06244992Phase 1RecruitingPrimary

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06293651Phase 1RecruitingPrimary

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

NCT06418061Phase 1Recruiting

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Scroll to load more

Research Network

Activity Timeline